Advanced Weight Loss Stack

20.2% body weight gone at 72 weeks, and that was the average, not the ceiling. Tirzepatide (LY3298176, CAS 2023788-19-2) is a 39-amino acid acylated lipopeptide sold as Zepbound for obesity and Mounjaro for type 2 diabetes. It activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously. The dual receptor mechanism separates tirzepatide from single-target GLP-1 drugs like semaglutide. GIP receptor activation improves fat metabolism and may reduce the nausea burden that limits GLP-1-only treatment. GLP-1 receptor activation suppresses appetite, slows gastric emptying, and boosts insulin secretion. Those two pathways working together produce weight loss and glycemic control that neither achieves alone. SURMOUNT-1 (PMID 35658024, n=2,539) showed dose-dependent results at 72 weeks: 15.0% weight loss at 5 mg, 19.5% at 10 mg, and 22.5% at 15 mg. SURMOUNT-5 (PMID 40353578, n=751) ran a direct comparison; tirzepatide reached 20.2% versus semaglutide's 13.7%. Roughly one in five tirzepatide patients lost 30% or more of their body weight. The r/Zepbound community (180,000+ members) confirms what the trials found. Appetite suppression starts within days. Most users stabilize at 7.5 to 12.5 mg rather than pushing to the maximum 15 mg dose. Cost and insurance coverage remain the biggest barriers. Weight regain after stopping is well-documented; about two-thirds of lost weight returns within a year of discontinuation.

2.8 kg of extra fat loss versus placebo over 12 weeks. That was the Phase IIa result for the AOD-9604 peptide (also called hGH fragment 177-191 or hGH frag, CAS 221231-10-3) in roughly 300 obese adults taking 1 mg orally per day (Obesity Research 2000, PMID 10950816). Then the larger Phase IIb trial with 536 subjects ran for 24 weeks, added strict diet and exercise controls, and missed its primary endpoint. Metabolic Pharmaceuticals terminated the program in 2007. The mechanism is specific. AOD-9604 activates beta-3 adrenergic receptors on adipocytes, triggering lipolysis while blocking lipogenesis. Unlike full-length growth hormone, it does not bind the GH receptor. Blood sugar stays flat. IGF-1 stays flat. Styer and colleagues confirmed this receptor selectivity in beta-3-AR knockout mice (Endocrinology 2001, PMID 11713213), where the lipolytic effect disappeared completely. Community use looks different from the clinical program. Most users inject 300 to 500 mcg subcutaneously each morning on an empty stomach. That dose range comes from converting the 1 mg oral clinical dose using an estimated 40% oral bioavailability from animal models. No published human SC pharmacokinetic study has validated this conversion. Across 50 to 150 Reddit threads in r/Peptides, the consensus is consistent: AOD-9604 is a mild add-on, not a primary fat loss tool. It performs best when stacked with CJC-1295 and Ipamorelin in a caloric deficit. Anyone expecting GLP-1-level results will be disappointed.